FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979760472> ?p ?o ?g. }

• W2979760472 abstract "Abstract Abstract 892 Bosutinib (SKI-606) is an orally available, dual Src/Abl tyrosine kinase inhibitor (TKI) with minimal inhibitory activity against PDGFR or c-kit. This open-label, phase 1/2 study evaluated the safety and efficacy of bosutinib as third-line therapy in patients with Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML). Adults (aged ≥18 years) who had failed prior imatinib (IM) therapy and were resistant or intolerant to dasatinib (DAS; n = 35 and n = 51, respectively) or resistant to nilotinib (NIL; n = 28) received oral daily treatment with a starting dose of 500 mg bosutinib. Of the 118 patients enrolled, 46% were male, the median age was 56 years (range, 20–79 years), and the median time from CML diagnosis to start of bosutinib was 6.7 years (range, 0.6–19.2 years). The median daily dose of bosutinib was 446 mg (range, 140–563 mg). At week 24, 26% of patients achieved a major cytogenetic response (MCyR), including 13% with a complete cytogenetic response (CCyR; see Table). Cumulative response rates were 34% for MCyR and 22% for CCyR. The majority (81%) of patients who achieved a MCyR still retained their response as of the data snapshot date (median follow-up duration of 23 months). Comparable rates of response were observed across Bcr-Abl kinase domain mutations, except for the T315I mutation. The most frequently reported treatment-emergent adverse events (TEAEs; ≥20% of patients, all grades) were diarrhea (83%), nausea (45%), vomiting (36%), rash (26%), headache (25%), and fatigue (22%). The incidence of TEAEs was generally similar for DAS-resistant, DAS-intolerant, and NIL-resistant patients. Gastrointestinal events were predominantly grade 1/2, had an early onset, and usually subsided within the first 4 weeks of treatment. The only grade 3/4 TEAE reported in ≥5% of patients was diarrhea (8%). One grade 3 pleural effusion was observed in a patient with concomitant pneumonia and a history of recurrent pleural effusions on DAS. Grade 3/4 hematologic laboratory abnormalities included thrombocytopenia (23%), neutropenia (16%), and anemia (8%); all were usually transient. Other grade 3/4 laboratory abnormalities (≥5% of patients) included elevations of magnesium (12%), alanine transaminase (ALT; 7%), and lipase (5%). Grade 3/4 transaminase elevations were observed more frequently in NIL-resistant patients (ALT, 18% [grade 4, n = 1]; aspartate transaminase [AST], 11% [grade 4, n = 1]) compared with DAS-resistant/intolerant patients (ALT, 3–4%; AST, 0–3%). On-treatment QTcF interval prolongation was observed in 13 patients (11%), but was only grade 1/2 (≤500 msec) with a reported rate of arrhythmia of <1%. Adverse events led to treatment discontinuation in 27% of DAS-intolerant patients, 14% of DAS-resistant patients, and 11% of NIL-resistant patients; thrombocytopenia (4%), neutropenia (3%), and increased ALT (3%) were the only events resulting in discontinuation of >2 patients. In conclusion, bosutinib has an acceptable safety profile in patients with CP CML following failure of IM and DAS or NIL, with primarily low-grade and transient gastrointestinal TEAEs. Bosutinib also demonstrated clinical activity as a third-line therapy, with over one-third of patients achieving a MCyR. These results emphasize the therapeutic potential of bosutinib for CP CML patients with resistance or, particularly, intolerance to other second-generation TKI therapies. Table 1: Table. IM failure + DAS resistant IM failure + DAS intolerant IM failure + NIL resistant Total Cytogenetic response at week 24, n (%) Evaluablea 26 29 15 70 MCyR 5 (19) 9 (31) 4 (27) 18 (26) CCyR 2 (8) 5 (17) 2 (13) 9 (13) Cytogenetic response(cumulative), n (%) Evaluableb 32 38 21 91 MCyR 10 (31) 14 (37) 7 (33) 31 (34) CCyR 3 (9) 13 (34) 4 (19) 20 (22) Patients retaining MCyR at time of latest data snapshot, n (%) 7 (70) 11 (79) 7 (100) 25 (81) Median follow-up time (range), months 12 (3–47) 27 (0.3–43) 7 (1–42) 23 (0.3–47) Median duration of MCyR (range), weeks 24 (6–64) 68 (7–124) 18 (6–185) 37 (6–185) a Evaluable patients had baseline and week 24 cytogenetic assessments. Patients who had experienced early progression or death before having a post-baseline assessment were also evaluable. b Evaluable patients had baseline and post-baseline cytogenetic assessments. Patients who had experienced early progression or death before having a post-baseline assessment were also evaluable. Disclosures: Khoury: BMS, Novartis: Honoraria. Kim:BMS, Novartis, Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Gambacorti-Passerini:Pfizer Inc: Research Funding. Hochhaus:Novartis, BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer Inc: Research Funding. Dorlhiac-Llacer:Novartis: Research Funding; BMS: Research Funding; Pfizer Inc: Research Funding. Kelly:Pfizer Inc: Employment, Equity Ownership. Besson:Pfizer Inc: Employment, Equity Ownership. McMullan:Pfizer Inc: Employment, Equity Ownership. Kantarjian:Pfizer, Novartis, BMS: Research Funding; Novartis: Consultancy. Cortes:Pfizer Inc: Consultancy, Research Funding." @default.
• W2979760472 created "2019-10-18" @default.
• W2979760472 creator A5005802663 @default.
• W2979760472 creator A5015101485 @default.
• W2979760472 creator A5015377056 @default.
• W2979760472 creator A5021391637 @default.
• W2979760472 creator A5026190297 @default.
• W2979760472 creator A5035964802 @default.
• W2979760472 creator A5036874214 @default.
• W2979760472 creator A5038251341 @default.
• W2979760472 creator A5052875031 @default.
• W2979760472 creator A5056473514 @default.
• W2979760472 creator A5059723473 @default.
• W2979760472 creator A5080153027 @default.
• W2979760472 creator A5083442651 @default.
• W2979760472 creator A5090435894 @default.
• W2979760472 date "2010-11-19" @default.
• W2979760472 modified "2023-10-15" @default.
• W2979760472 title "Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib" @default.
• W2979760472 doi "https://doi.org/10.1182/blood.v116.21.892.892" @default.
• W2979760472 hasPublicationYear "2010" @default.
• W2979760472 type Work @default.
• W2979760472 sameAs 2979760472 @default.
• W2979760472 citedByCount "1" @default.
• W2979760472 crossrefType "journal-article" @default.
• W2979760472 hasAuthorship W2979760472A5005802663 @default.
• W2979760472 hasAuthorship W2979760472A5015101485 @default.
• W2979760472 hasAuthorship W2979760472A5015377056 @default.
• W2979760472 hasAuthorship W2979760472A5021391637 @default.
• W2979760472 hasAuthorship W2979760472A5026190297 @default.
• W2979760472 hasAuthorship W2979760472A5035964802 @default.
• W2979760472 hasAuthorship W2979760472A5036874214 @default.
• W2979760472 hasAuthorship W2979760472A5038251341 @default.
• W2979760472 hasAuthorship W2979760472A5052875031 @default.
• W2979760472 hasAuthorship W2979760472A5056473514 @default.
• W2979760472 hasAuthorship W2979760472A5059723473 @default.
• W2979760472 hasAuthorship W2979760472A5080153027 @default.
• W2979760472 hasAuthorship W2979760472A5083442651 @default.
• W2979760472 hasAuthorship W2979760472A5090435894 @default.
• W2979760472 hasConcept C126322002 @default.
• W2979760472 hasConcept C143998085 @default.
• W2979760472 hasConcept C197934379 @default.
• W2979760472 hasConcept C2777063308 @default.
• W2979760472 hasConcept C2777413986 @default.
• W2979760472 hasConcept C2777583451 @default.
• W2979760472 hasConcept C2778208673 @default.
• W2979760472 hasConcept C2778375690 @default.
• W2979760472 hasConcept C2778570526 @default.
• W2979760472 hasConcept C2778729363 @default.
• W2979760472 hasConcept C2779536868 @default.
• W2979760472 hasConcept C2780580376 @default.
• W2979760472 hasConcept C29730261 @default.
• W2979760472 hasConcept C71924100 @default.
• W2979760472 hasConcept C90924648 @default.
• W2979760472 hasConceptScore W2979760472C126322002 @default.
• W2979760472 hasConceptScore W2979760472C143998085 @default.
• W2979760472 hasConceptScore W2979760472C197934379 @default.
• W2979760472 hasConceptScore W2979760472C2777063308 @default.
• W2979760472 hasConceptScore W2979760472C2777413986 @default.
• W2979760472 hasConceptScore W2979760472C2777583451 @default.
• W2979760472 hasConceptScore W2979760472C2778208673 @default.
• W2979760472 hasConceptScore W2979760472C2778375690 @default.
• W2979760472 hasConceptScore W2979760472C2778570526 @default.
• W2979760472 hasConceptScore W2979760472C2778729363 @default.
• W2979760472 hasConceptScore W2979760472C2779536868 @default.
• W2979760472 hasConceptScore W2979760472C2780580376 @default.
• W2979760472 hasConceptScore W2979760472C29730261 @default.
• W2979760472 hasConceptScore W2979760472C71924100 @default.
• W2979760472 hasConceptScore W2979760472C90924648 @default.
• W2979760472 hasLocation W29797604721 @default.
• W2979760472 hasOpenAccess W2979760472 @default.
• W2979760472 hasPrimaryLocation W29797604721 @default.
• W2979760472 hasRelatedWork W1019829508 @default.
• W2979760472 hasRelatedWork W129265093 @default.
• W2979760472 hasRelatedWork W132577078 @default.
• W2979760472 hasRelatedWork W2510277050 @default.
• W2979760472 hasRelatedWork W2530983853 @default.
• W2979760472 hasRelatedWork W2531681895 @default.
• W2979760472 hasRelatedWork W2538667471 @default.
• W2979760472 hasRelatedWork W2549386047 @default.
• W2979760472 hasRelatedWork W2560046425 @default.
• W2979760472 hasRelatedWork W2574923075 @default.
• W2979760472 hasRelatedWork W2585952718 @default.
• W2979760472 hasRelatedWork W2586256503 @default.
• W2979760472 hasRelatedWork W2586559902 @default.
• W2979760472 hasRelatedWork W2586659163 @default.
• W2979760472 hasRelatedWork W2586889727 @default.
• W2979760472 hasRelatedWork W2910542347 @default.
• W2979760472 hasRelatedWork W2979405246 @default.
• W2979760472 hasRelatedWork W2980027653 @default.
• W2979760472 hasRelatedWork W3015410279 @default.
• W2979760472 hasRelatedWork W78746003 @default.
• W2979760472 isParatext "false" @default.
• W2979760472 isRetracted "false" @default.
• W2979760472 magId "2979760472" @default.
• W2979760472 workType "article" @default.